Evidence map›Paper›PMID 38352379›Full record

ArticlemedRxiv : the preprint server for health sciences2024

A functional genomic framework to elucidate novel causal non-alcoholic fatty liver disease genes.

Peter Saliba-Gustafsson, Johanne M Justesen, Amanda Ranta, Disha Sharma, Ewa Bielczyk-Maczynska, Jiehan Li, Laeya A Najmi, Maider Apodaka, Patricia Aspichueta, Hanna M Björck and 10 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 9 institutions in 4 countries.

Peter Saliba-GustafssonDepartment of Medicine, Division of Cardiovascular Medicine and Cardiovascular Institute, Stanford University, Stanford, CA, USA.ORCID 0000-0002-7807-9009
Johanne M JustesenDepartment of Medicine, Division of Cardiovascular Medicine and Cardiovascular Institute, Stanford University, Stanford, CA, USA.
Amanda RantaDepartment of Medicine, Division of Cardiovascular Medicine and Cardiovascular Institute, Stanford University, Stanford, CA, USA.
Disha SharmaDepartment of Medicine, Division of Cardiovascular Medicine and Cardiovascular Institute, Stanford University, Stanford, CA, USA.
Ewa Bielczyk-MaczynskaDepartment of Medicine, Division of Cardiovascular Medicine and Cardiovascular Institute, Stanford University, Stanford, CA, USA.
Jiehan LiDepartment of Medicine, Division of Cardiovascular Medicine and Cardiovascular Institute, Stanford University, Stanford, CA, USA.
Laeya A NajmiDepartment of Medicine, Division of Cardiovascular Medicine and Cardiovascular Institute, Stanford University, Stanford, CA, USA.
Maider ApodakaUniversity of the Basque Country (UPV/EHU), Faculty of Medicine and Nursing, Department of Physiology, Leioa, Spain.
Patricia AspichuetaUniversity of the Basque Country (UPV/EHU), Faculty of Medicine and Nursing, Department of Physiology, Leioa, Spain.
Hanna M BjörckDivision of Cardiovascular Medicine, Centre for Molecular Medicine, Department of Medicine, Solna, Karolinska Inistitutet, Stockholm, Karolinska University Hospital, Solna, Sweden.
Per ErikssonDivision of Cardiovascular Medicine, Centre for Molecular Medicine, Department of Medicine, Solna, Karolinska Inistitutet, Stockholm, Karolinska University Hospital, Solna, Sweden.
Anders Franco-CerecedaDepartment of Molecular Medicine and Surgery, Karolinska Inistitutet, Stockholm, Sweden.
Mike GloudemansDepartment of Pathology, Stanford University School of Medicine, CA, USA.
Endrina MujicaDepartment of Immunology, Genetics and Pathology, Uppsala University, Sweden.
Marcel den HoedDepartment of Immunology, Genetics and Pathology, Uppsala University, Sweden.ORCID 0000-0001-8081-428X
Themistocles L AssimesDepartment of Medicine, Division of Cardiovascular Medicine and Cardiovascular Institute, Stanford University, Stanford, CA, USA.ORCID 0000-0003-2349-0009
Thomas QuertermousDepartment of Medicine, Division of Cardiovascular Medicine and Cardiovascular Institute, Stanford University, Stanford, CA, USA.ORCID 0000-0002-7645-9067
Ivan Carcamo-OriveDepartment of Medicine, Division of Cardiovascular Medicine and Cardiovascular Institute, Stanford University, Stanford, CA, USA.
Chong Y ParkDepartment of Medicine, Division of Cardiovascular Medicine and Cardiovascular Institute, Stanford University, Stanford, CA, USA.
Joshua W KnowlesDepartment of Medicine, Division of Cardiovascular Medicine and Cardiovascular Institute, Stanford University, Stanford, CA, USA.
Cardiovascular Institute of the South · USKarolinska University Hospital · SEUniversity of the Basque Country · ESUppsala University · SEIkerbasque · ESKarolinska Institutet · SEStanford University · USUniversity of Minnesota · USVA Palo Alto Health Care System · US

Funding

Stanford Islet Research CoreP30DK116074 · NIDDK · STANFORD UNIVERSITY · PI Seung K Kim · 2017 to 2026
$19.5M
Characterization of novel insulin resistance genes by gene editing, high-throughput phenotyping and in vivo studiesR01DK120565 · NIDDK · STANFORD UNIVERSITY · PI KNOWLES, JOSHUA WILEY · 2019 to 2023
$3.2M
Mechanisms of NAT2 Regulation of Insulin Resistance and Mitochondrial DysfunctionR01DK116750 · NIDDK · STANFORD UNIVERSITY · PI KNOWLES, JOSHUA WILEY · 2019 to 2023
$2.4M
Beyond GWAS of insulin resistance: An integrated approach to translate genetic association to functionR01DK106236 · NIDDK · STANFORD UNIVERSITY · PI KNOWLES, JOSHUA WILEY · 2016 to 2020
$2.4M
NIDDK NIH HHS P30 DK116074NIDDK NIH HHS R01 DK106236NIDDK NIH HHS R01 DK116750NIDDK NIH HHS R01 DK120565
6 · The paper itself

Abstract

Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver pathology in western countries, with serious public health consequences. Efforts to identify causal genes for NAFLD have been hampered by the relative paucity of human data from gold-standard magnetic resonance quantification of hepatic fat. To overcome insufficient sample size, genome-wide association studies using NAFLD surrogate phenotypes have been used, but only a small number of loci have been identified to date. In this study, we combined GWAS of NAFLD composite surrogate phenotypes with genetic colocalization studies followed by functional in vitro screens to identify bona fide causal genes for NAFLD. Approach & Results: We used the UK Biobank to explore the associations of our novel NAFLD score, and genetic colocalization to prioritize putative causal genes for Conclusions: Complementary genetic and genomic approaches are useful for the identification of NAFLD genes. Our data supports

Indexed as

CRISPR interferencegenetic epidemiologyHepaRG cellsNAFLDPerturb-seq

Identifiers

PMID38352379
PMCPMC10863038
OpenAlexW4391519576

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.